FzioMed

FzioMed is a long-standing, privately-held medical device company focused on the surgical adhesion prevention market. Its commercialized product portfolio is built on a proprietary dual-polymer gel technology (CMC/PEO) that acts as a physical barrier to reduce adhesion formation. With over two decades of clinical use, treatment of more than one million patients, and peer-reviewed evidence across several surgical areas, the company is an established player in a niche but critical segment of surgical care. It operates primarily through a distributor network to market its approved products globally.

Proprietary dual-polymer gel combining carboxymethylcellulose (CMC) for tissue adherence and polyethylene oxide (PEO) to disrupt fibrin and inflammatory cytokine deposition, forming an absorbable physical barrier to prevent postsurgical adhesions.

The adhesion prevention market includes competitors offering gels, films, and sprays based on hyaluronic acid, regenerated cellulose, and other polymers. FzioMed competes by emphasizing the unique dual-polymer mechanism, tissue adherence, and a long-term safety record. Key competitors are typically larger, diversified medical device companies with broader portfolios.